Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023Business Wire • 02/20/24
Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024Business Wire • 02/14/24
Summit Therapeutics to Present at Oppenheimer's 34th Annual Healthcare Life Sciences ConferenceBusiness Wire • 02/07/24
Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/08/24
Summit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/03/24
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023Business Wire • 11/07/23
Laura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical DevelopmentBusiness Wire • 11/02/23
Ivonescimab's Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023PRNewsWire • 11/02/23
Summit Therapeutics to Host Q3 2023 Financial Results & Operational Progress Call on November 7, 2023Business Wire • 10/26/23
H. Jack West, MD, Renowned Oncologist & Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical DevelopmentBusiness Wire • 10/19/23
Summit Therapeutics Appoints Proven Biotech Leader Manmeet S. Soni as Chief Operating OfficerBusiness Wire • 10/16/23
Week In Review: Hengrui Out-Licenses Novel Anti-Inflammatory To One Bio In $1 Billion DealSeeking Alpha • 08/20/23
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023Business Wire • 08/09/23
Summit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023Business Wire • 08/02/23
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Summit Therapeutics Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsPRNewsWire • 07/10/23
Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023Business Wire • 06/04/23